JonathanKolitzMD

PubMed

• CLL crosstalk with naïve T cells enhances the differentiation of IL-22-producing T cells and CLL -cell survival.
  Gerardo Ferrer, Florencia Palacios, Pui Yan Chiu, Kelly Wong, Alberto Bueno-Costa
  Leukemia. 2024-11-22
• 1 citations
  Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia.
  Andrew Stiff, Maarten Fornerod, Bailee N Kain, Deedra Nicolet, Benjamin J Kelly
  Nature Genetics. 2024-11-01
• White blood cell count levels are associated with inflammatory response and constitute independent outcome predictors in adult patients with acute myeloid leukemia age...
  Michael Ozga, Deedra Nicolet, Krzysztof Mrózek, Christopher J Walker, James S Blachly
  American Journal of Hematology. 2024-11-01

Journal Articles

• NF1 Mutations Are Recurrent in Adult Acute Myeloid Leukemia and Confer Poor Outcome  
  Eunice S Wang, Bayard L Powell, Richard M Stone, John C Byrd, Clara D Bloomfield, Alice Mims, Andrew J Carroll, Jonathan E Kolitz, James S Blachly, Nature
• A complex variant Philadelphia chromosome translocation involving chromosomes no. 11, 14, and 22 in a case of chronic myelogenous leukemia.  
  Kolitz, J.E., Schulman, P., Kardon, N., Budman, D.R., Vinciguerra, V.P., Broekman, A. and Degnan, T.J, Cancer Genetics and Cytogenetics 1981; 4:185-188
• Human Interleukin 2 gene is located on chromosome 4.  
  Sykora, K.W., Kolitz, J., Szabo, P., Grzeschik, K.H., Moore, M.A.S. and Mertelsmann, R, Cancer Investigation 1984; 2:261-265
• Polyclonal expansion of activated T-Lymphocytes in patients treated with recombinant interleukin 2.  
  Kolitz, J.E., Welte, K. Holloway, K., Merluzzi, V.J., Bradley, E.C., Konrad, M., Engert, A., Polivca, A., Gabrilove, J.L., Groshen, S., Sykora, K.W., Miller, G.A., Fie..., J. Biol. Resp. Modifiers 1987; 6:412-429
• Defect of T. cell activation in common variable immunodeficiency is restored with phorbol myristate acetate.  
  Fiedler, W., Sykora, K.W., Welte, K., Kolitz, J., Cunningham-Rundles, C., Souza, L., Miller, G., Holloway, K., Mertelsmann, R, Clin. Immunol. Immunopathol. 1987; 44:206-218
• Distinction of partially purified human natural killer cytotoxic factor from recombinant human tumor necrosis factor and recombinant human lymphotoxin.  
  Bialas, T., Kolitz, J., Levi, E,. Polivka, A., Oez, S., Miller, G., Welte, K, Cancer Res. 1988; 48:891-898
• Randomized study of 13-cis retinoic acid versus placebo in the myelodysplastic disorders.  
  Koeffler, H.P., Heitjan, D., Mertelsmann, R., Kolitz, J.E, Schulman, P., Itri, L., Gunter, P., Besa, E, Blood 1988; 71:703-708
• Phase I trial of intraperitoneal recombinant IL-2 in ovarian cancer.  
  Chapman, P., Kolitz, J.E., Hakes, T., Gabrilove, J., Welte, K., Engert, A., Merluzzi, V.J., Bradley, E., Oettgen, H., Mertelsmann, R, Invest. New Drugs 1988; 6: 179-188
• Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.  
  Kolitz, J.E., Wong, G.Y., Welte, K., Merluzzi, V.J., Engart, A., Bialas, T., Bradley, E.C., Konrad, M., Grecco, C., Oettgen, H.F., Mertelsmann, R, J. Biol. Resp. Modifiers 1988; 7: 457-472
• Anti-tumor efficacy of interleukin-2-activated killer cells in human neuroblastoma ex-vivo.  
  Atzpodien, J., Gulati, S.E., Kwon, J.H., Kushner, B.H., Shimazaki, C., Buhrer, C., Oz, S., Kolitz, J.E., Clarkson, B.D, Exper. Cell. Biol. 1988; 56:236-244
• Ewing’s sarcoma: ex-vivo sensitivity towards natural (NK) and lymphokine-activated (LAK) killing.  
  Atzpodien, J., Gulati, S., Buhrer, C., Oz, S., Khon, J.H., Kolitz, J.E., Clarkson, B, Oncology 1988; 45:437-443
• Cell-mediated toxicity of interleukin-2-activated lymphocytes against autologous and allogeneic human myeloma cells.  
  Shimazaki, C., Atzpodien, J., Wisniewski, D., Gulati, S.C., Kolitz, J.E., Fried, J., Clarkson, B.D, Acta. Haematol. 1988; 80:203-209
• A phase II study of human interleukin 2 in metastatic renal cell cancer and melanoma.  
  Lindemann, A., Herrman, F., Schmidt, R.E., Diehl, V., Kloke, O.,Gamm, H., Hayungs, J., Oster, W., Bohen, M., Kolitz, J.E., Hoffken, K., Mertelsmann, R, Cancer Immunol. Immunother. 1989; 28:275-281
• The pharmacokinetics of recombinant IL-2 in humans.  
  Konrad, M.W., Hemstract, G., Hersh, E., Mansell, P., Mertelsmann, R., Kolitz, J.E., Bradley, E.C, Cancer Res. 1990; 50:2009-2017
• Treatment of Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in blast crisis with high dose cytosine arabinoside (HDARAC).  
  Kempin, S., Arlin, Z., Berman, E., Gee, T., Mertelsmann, R., Andreeff, M., Kolitz, J., Jhanwar, S., Myers, J., Clarkson, B, Leukemia & Lymphoma 1991; 4:11-116
• Results of a ranodomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute no...  
  Berman, E., Heller, G., Santorsa, J., McKenzie, S., Gee, T.,Kempin, S., Gulati, S., Andreeff, M., Kolitz, J., Gabrilove, J., Reich, L., Mayer, K., Keefe, D., Trainor, ..., Blood 1991; 77:1666-1674
• Mitoxantrone, etoposide, mitoguazone and vinblastine chemotherapy in relapsed and refractory lymphomas.  
  Crown, J.P., Gulati, S.C., Straus, D.J., Kolitz, J., Heelan, R., O’Brien, J., Straus, D.J., M., Lee, B.J., Portlock, C., Bertino, J, Invest. New Drugs 1991; 9:185-186
• Study of leukemia a of large granular lymphocytes using modern modalities.  
  Sun, T., Schulman, P., Kolitz, J.E., Brody, J., Koduru, P., Muuse, W., Broome, J, Amer. J. Hematol. 1992; 40:135-145
• Phase I evaluation of a water soluble etoposide prodrug,etoposide phosphate given as a 5-minute infusion on days 1, 3, 5 in patients with solid tumors.  
  Budman, D.R., Igwemezie, L.N.,Kaul, S., Behr, J., Lichtman, S., Schulman, P., Vinciguerra, V., Allen, S.L., Kolitz, J., Hock,K., O’Neill, K., Schacter, L., Barbhaiya R.H, J. Clin. Oncol. 1994; 12:1902-1909
• Peripheral T cell lymphoma in a patient with sinus histiocytosis and massive lymphadenopathy: molecular and cytogenetic studies.  
  Koduru, P., Susin, M., Kolitz, J.E., Brody, J., Amorosi, E., Budman, D, Amer. J. Hematol. 1995; 48:192-200
• Clinical and morphologic features of cases of trisomy 13 in acute non- lymphocytic leukemia.  
  Soni, M., Brody, J.,Allen, S., Schulman, P., Kolitz, J., Rai, K., Broome, J.D., Koduru, P.R.K, Leukemia 1996; 10:619-623
• Examples of in vivo isotype class switching in IgM+ chronic lymphocytic leukemia B cells.  
  Fais, F., Sellars, B., Yan, X-J., Dono, M., Allen, S.L., Budman, D., Dittmar, K., Kolitz, J., Lichtman, S.M., Schulman, P., Schuster, M., Vinciguerra, V.P., Rai, K., S..., J. Clin. Invest. 1996; 98:1659-1666
• Granulocyte-colony stimulating factor (FilgrastimR) accelerates granulocyte and platelet recovery following intensive postremission chemotherapy for acute myeloid leuk...  
  Moore, J.O., Dodge, R.K., Amrein, P.C., Kolitz, J., Lee, E.J., Powell, B., Godfrey, S., Robert, F., Schiffer, C.A, Blood 1997; 89:780-788
• Clonal expansion within the CD4+CD57+ and CD8+CD57+ T-cell subsets in chronic lymphocytic leukemia.  
  Serrano, D., Monteiro, J., Allen, S.L., Kolitz, J., Schulman, P., Lichtman, S.M., Buchbinder, A., Vinciguerra, V., Chiorazzi, N., Gregersen, P.K, J Immunology 1997; 158:1492-1499
• Correlation between mutation in p53, p53 expression, cytogenetics, histologic type and duration of survival in patients with B-cell Non-Hodgkin’s Lymphoma.  
  Koduru, P.R.K., Raju, K., Vadmal, V., Menezes, G., Susin, M., Kolitz, J., Broome, J.D, Blood 1997; 90:4078-4091
• Join now to see all

Books/Book Chapters

• Development, Testing, and Use of Biologically Active Substances in Cancer Therapy. 
  Chapter: Treatment of Cancer with Interleukin 2 
  Mertelsmann, R., Welte, K., Sykora, K.W., Kolitz, J., Holloway, K., Fiedler, W., Miller, G., Merluzzi, V., Venuta, S., Engert, A., Stein, C., Polivka, A., Levi, EEditors: Schuff-Werner P., Pfizenmaier, K.Zuckschwerdt Verlag, Munich
• Cellular and Molecular Biology of Lymphokines. 
  Chapter: The role of interleukin 2 in human immunodeficiency states 
  Page 755 - 789Welte, K., Kolitz, J.E., Merluzzi, V.J., Flomenberg, N., Engert, A., Miller, G.A.,Holloway, K., Sykora, K.W., Venuta, S., Bradley, E., O’Reilly, R.J. Oettgen, H.F., Me...Editors: Sorg, C. and Schimpl, A.Academic Press, New York
• Modern Trends in Human Leukemia, Vol. VII. 
  Chapter: Cytokines with possible clinical utility 
  Page 97 - 102Mertelsmann R., Kolitz, J., Welte, K., Herrmann, FEditors: Neth, R., Gallo, R.C.
• Interleukin 2 and Killer Cells in Cancer. 
  Chapter: Synergism between cyclophosphamide and interleukin-2 
  Page 125 - 132Mertelsmann, R., Lindemann, A., Kolitz, J., Herrmann, FEditors: Lotzova, E. and Herberman, R.B.CRC Press
• Update on clinical trials of chemotherapy and bone marrow transplantation in acute myelogenous leukemia at Memorial Sloan-Kettering Cancer Center (MSKCC) 1966 to 1989. 
  Page 239 - 272Clarkson, B., Berman, E., Little, C., Andreeff, M., Kempin, S., Kolitz, J., Gabrilove, J., Cunningham, I., Castro-Malaspina, H., Gulati, S., O’Reilly, R., Gee, TEditors: Gale, R.P.Wiley-Liss, Inc, New York
• Conn’s Current Therapy 2000. 
  Chapter: Chronic Leukemias 
  Page 425 - 432Kolitz, J.E., Lichtman, S.MW.B. Saunders and Co
• Cancer in the Elderly. 
  Chapter: Leukemias, Lymphomas, Myelomas 
  Page 361 - 418Lichtman, S.M., Kolitz, JEditors: Hunter, C.P., Johnson, K.A., Muss, H.Marcel Dekker, Inc, New York
• Oncology: An evidence-based approach. 
  Chapter: Acute Myeloid Leukemia and the Myelodysplastic Syndromes 
  Kolitz, J.EEditors: Chang, A.E., Ganz, P.A., Hayes, D.F., Kinsella, T., Pass, H.I., Schiller, J.H., Stone, R.M., Streche.Springer
• Cancer in the Elderly. 
  Chapter: Multiple myeloma 
  Kolitz, J.E., Mazj, S., Lichtman, S.MEditors: Hunter, C.P., Johnson, K.A., Muss, H.Marcel Dekker, Inc, New York
• The Acute Leukemias In: Conn’s Current Therapy 2008. 
  Kolitz, J.EW.B. Saunders and Co
• Join now to see all

Abstracts/Posters

• Distinct Gene Expression Profiles and Mutations Associate with Outcome in Younger Adults with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (Alliance)
  Jonathan E. Kolitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• CLL B Cells Develop Resistance to Ibrutinib By Reinvigorating the IL-4R - IL-4 Axis Blocked By BrutonÍs Tyrosine Kinase Inhibitors Including Acalabrutinib and Zanubrut...
  Jonathan E. Kolitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Next-Generation RNA Sequencing-Based Analysis Identifies a Novel Set of Prognostic Micrornas (miRs) in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)
  Jonathan E. Kolitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• The 2017 European Leukemianet Genetic Risk Classification Performs Poorly in Older Patients with Acute Myeloid Leukemia (AML) and Should be Refined to Identify Patient...
  Jonathan E. Kolitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylatin...
  Jonathan E. Kolitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Personalized Oncology in Acute Myeloid Leukemia (AML): Validation of the Prognostic Value of the Knowledge Bank Algorithm in Patients (Pts) Treated on Cancer and Leuke...
  Jonathan E. Kolitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Non-Hodgkin’s lymphoma in the elderly - a pilot trial of thiotepa, novantrone, oncovin and prednisone (T-NOP).
  Lichtman, S.M., Fusco, D., Vinciguerra, V., Kolitz, J., Budman, D.R., Zhukovsky, D., Mittelman, A, Fifth International Conference Malignant Lymphoma, Lugano, Switzerland
• Initial studies of a water-soluble etoposide: etoposide phosphate.
  Budman, D.R., Igwemezie, L., Behr, J., Lichtman, S., Schacter, L., Schulman, P., Vinciguerra, V., Allen, S.L., Kolitz, J., Hock, K., O’Neill, K., Kaul, S, 18th International Congress of Chemotherapy 1993; 843
• Mutations in p53 gene are frequent in diffuse large cell histologic type of B-cell Non-Hodgkin’s lymphoma.
  Koduru, P.R.K., Raju, K., Tse, W., Kolitz, J., Broome, J.D, Proc. International Lymphoma Conference, Lugano
• Activation of the interleukin 2 gene in human lymphocytes.
  Sykora, K.W., Kolitz, J., Welte, K., Miller, G. and Mertelsmann, R, Lymphokine Res. 1984; 3:275
• Interleukin 2 and leukemia derived growth factor requirements of the colony assay for acute lymphoblastic leukemia and chronic lymphocytic leukemia.
  Miller, G.A., Welte, K., Holloway, K., Sykora, K.W., Kolitz, J., Moore, M.A.S. and Mertelsmann, R, Lymphokine Res. 1984; 3:261
• A mutiple dose phase I trial of recombinant interleukin 2 in advanced malignancy.
  Kolitz, J.E., Holloway, K., Welte, K., Sykora, K.W., Miller G., Fiedler, W., Bradley, E., Oettgen, H., Clarkson, B.D., and Mertelsmann, R, Proc. Amer. Soc. Clin, Oncol. 1985; 4:228
• Defective interleukin 2 production and lymphocyte proliferation in patients with common variable immunodeficiency is not due to gross deletions or rearrangements of th...
  Sykora, K.W., Fiedler, W., Kolitz, J., Cunningham-Rundles, C., Welte, K., Souza, L., Miller, G., Holloway, K., Mertelsmann, R, Exp. Hematol. 1985; 5:421
• Structure and expression of the IL2 gene in patients with AIDS and AIDS related complex.
  Sykora, K.W., Riedel, N., Kolitz, J.E., Mullins, J.I., Mertelsmann, R, Blood 1985; 66(Suppl 1):117a
• In vivo enhancement of natural killer (NK) and lymphokine-activated killer (LAK) cell activity in patients treated with recombinant interleukin-2 and cyclophosphamide.
  Kolitz, J.E., Merluzzi, V.J., Holloway, K., Engert, A., Welte, K., Bradley, E., Sykora, K.W., Miller, G.A., Fiedler, W., Oettgen, H.F., Clarkson, B.D., Mertelsmann, R, Blood 1985; 66(Suppl 1):100a
• A phase II pilot study of intraperitoneal rIL-2 in ovarian cancer.
  Chapman, P., Hakes, T., Gabrilove, J.L., Kolitz, J.E., Welte, K., Merluzzi, V.J., Engert, A., Bradley E.C., Oettgen, H.F., Mertelsmann, R, Proc. Amer. Soc. Clin. Oncol. 1986; 5:231
• A phase I trial of recombinant interleukin 2 and cyclophosphamide in advanced malignancy.
  Kolitz, J.E., Merluzzi, V.J., Welte, K., Engert, A., Polivka, A., Bialas, T., Wong, G., Gnecco, C., Bradley, E., Oettgen, H., Mertelsmann, R, Proc. Amer. Soc. Clin. Oncol. 1986; 5:235
• Results of a comparative trial of idarubicin and cytarabine with daunorubicin and cytarabine in patients with untreated acute non-lymphocytic leukemia.
  Berman E., Gee, T.S., Kempin, S., Gulati, S., Andreeff, M., Gabrilove, J., Kolitz, J., Reich, L., Mayer, K., Miller, W., Raymond, G., Young, C.W., Clarkson B.D, Blood 1986; 68(Suppl 1):218a
• Comparative analysis of partially purified human natural killer cytotoxic factor, recombinant human tumor necrosis factor and recombinant human lymphotoxin.
  Bialas, T., Kolitz, J., Levi, E., Welte, K, Immunobiology 1987; 175:76
• Generation of lymphokine-activated killer (LAK) cells without Ficoll-Hypaque density-gradient separation: new applications for blood cell separators and implications f...
  Bialas, T., Welte, K., Kolitz, J., Flomenberg, N., Reich, L, Blood 1987; 70(Suppl 1):223a
• Low-dose cytosine-arabinoside (Ara-C) in acute non-lymphocytic leukemia (ANLL) and myelodysplastic syndromes (MDS): analysis of response and response mechanisms
  Andreeff, M., Kreis W., Miller W., Gee, T., Berman, E., Kolitz, J., Kempin, S., Straus, D., Reich, L., Tafuri, A., Espiritu E., Deere M., and Clarkson, B, Proc Amer. Soc. Clin. Oncol. 1987; 7:191
• A Phase I pilot trial of recombinant interferon-alpha-2a and recombinant interleukin 2 in the malignant low grade B cell diseases.
  Kolitz, J.E., Flomenberg, N.,Templeton, M.A., Warrell, Jr., R.P., Kempin, S., Levitt, D., Oettgen, H., Clarkson, B, Blood 1988; 72(Suppl 1):246a
• Results of a randomized trial comparing idarubicin/ cytosine arabinoside (Ara-C) with daunorubicin/Ara-C in adult patients with untreated acute nonlymphatic leukemia.
  Berman, E., Raymond, G., Gee, T.S., Kempin, S., Andreeff, M., Gulati, S., Kolitz, J., Gabrilove, J., Young, C.Y., Clarkson, B.D, Blood 1988; 7(Suppl 1):189a
• Cytogenetic response in chronic myelogenous leukemia with high dose hydroxyurea.
  Kolitz, J., Kempin, S., Berman, E., Jhanwar, S., Arlin, Z., Gee, T., Clarkson, B, Proc. Amer. Soc. Clin Oncol. 1989; 8:208
• Infectious complications of interleukin-2 therapy in patients with renal cell carcinoma and melanoma.
  Sterman, D., Bajorin, D., Reichman, B., Sternberg, C., Groeger, J., Kolitz, J., Reich, L., Sher, H., Cody, B., Gold, J, Proc. Amer. Soc. Clin Oncol. 1989; 8:192
• Join now to see all

Lectures

• Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 ... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Mutations in Genes Associated with Familial Predisposition to Myeloid Neoplasms: Their Frequency and Associations with Pretreatment Characteristics in Adult Patients (... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Musashi 2 Is Overexpressed in Poor Outcome CLL Patients and Their Proliferative Fraction and Silencing This Gene Induces Apoptosis and Increases Cell Adhesion and Move... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Clinical and Molecular Characteristics of Acute Myeloid Leukemia (AML) Patients with TP53 Mutations and TP73 Mutations 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• A Precision Medicine Heirarchical Classification Developed Using Variant Allele Frequency (VAF) for Treatment of Older Patients (Pts) with Acute Myeloid Leukemia (AML)... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Prognostic and Biologic Significance of Transfer RNA-Derived Small RNAs (tsRNAs) Expression in Younger Adult Patients (Pts) with Cytogenetically Normal Acute Myeloid L... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Genome-Wide Association Study (GWAS) Identifies a Significant Acute Myeloid Leukemia (AML) Susceptibility Locus Near BICRA 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enr... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ibrutinib Treatment Reduces Myeloid Derived Suppressor Cell Numbers and Function in Chronic Lymphocytic Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all

Other

• Interleukin 2 - Basic and Clinical Studies. 
  Kolitz, J.E., Mertelsmann, R., Welte, K, Cancer Bulletin (M.D. Anderson Hospital) 1987; 39:13-18
• Acute leukemia in adults. 
  Kolitz, J.E, Dis. Month 2008: 54:226-241